M. Son

发表

Differential Protective Effects of Exenatide, an Agonist of GLP-1 Receptor and Piragliatin, a Glucokinase Activator in Beta Cell Response to Streptozotocin-Induced and Endoplasmic Reticulum Stresses

Mi-kyung Kim, Jin-Hwan Cho, Jae-Jin Lee, 2013, PloS one.

Potentiation of cadmium-induced cytotoxicity by sulfur amino acid deprivation through activation of extracellular signal-regulated kinase1/2 (ERK1/2) in conjunction with p38 kinase or c-jun N-terminal kinase (JNK). Complete inhibition of the potentiated toxicity by U0126 an ERK1/2 and p38 kinase inh

K. Kang, M. Son, C. H. Lee, 2001, Biochemical pharmacology.

PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.

Mi-kyung Kim, M. Son, J. G. Kim, 2011, European journal of pharmacology.

PAR-1622 is a selective peroxisome proliferator-activated receptor γ partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention

Mi-kyung Kim, M. Son, J. G. Kim, 2009, Archives of pharmacal research.

Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists.

Eunkyung Kim, M. Son, Mi Kyung Kim, 2008, Bioorganic & medicinal chemistry letters.

Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control

M. Son, Yc Shin, E. Yang, 2010, International Journal of Obesity.

Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models

Mi-kyung Kim, M. Son, E. Yang, 2017, Archives of pharmacal research.

Glucose exposure pattern determines glucagon-like peptide 1 receptor expression and signaling through endoplasmic reticulum stress in rat insulinoma cells.

B. Kaang, Mi-kyung Kim, Ye-Hwang Cheong, 2011, Biochemical and biophysical research communications.

Proteomic Analysis of INS-1 Rat Insulinoma Cells: ER Stress Effects and the Protective Role of Exenatide, a GLP-1 Receptor Agonist

Mi-kyung Kim, Jin-Hwan Cho, Jae-Jin Lee, 2015, PloS one.

An Orally Active Cathepsin K Inhibitor, Furan-2-Carboxylic Acid, 1-{1-[4-Fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), Inhibits Osteoclast Activity in Vitro and Bone Loss in Ovariectomized Rats

Jun Long Lim, M. Son, S. H. Kim, 2006, Journal of Pharmacology and Experimental Therapeutics.

Potentiation of arsenic-induced cytotoxicity by sulfur amino acid deprivation (SAAD) through activation of ERK1/2, p38 kinase and JNK1: the distinct role of JNK1 in SAAD-potentiated mercury toxicity.

K. Kang, M. Son, C. H. Lee, 2001, Toxicology letters.

Synthesis and biological evaluation of chromone carboxamides as calpain inhibitors.

M. Son, Yong Sup Lee, S. Seo, 2005, Bioorganic & medicinal chemistry letters.

Dipeptidyl peptidase-4 inhibitor with β-amino amide scaffold: synthesis, SAR and biological evaluation.

M. Son, Mi Kyung Kim, Bong Jin Lee, 2012, Bioorganic & medicinal chemistry letters.

DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.

Mi-kyung Kim, Ye-Hwang Cheong, M. Son, 2012, Life sciences.

Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.

Ye-Hwang Cheong, M. Son, Mi Kyung Kim, 2011, Bioorganic & medicinal chemistry letters.

Role of glucose utilization in the restoration of hypophysectomy-induced hepatic cytochrome P450 2E1 by growth hormone in rats.

K. Kang, M. Son, S. H. Kim, 2000, Chemico-biological interactions.

PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.

Mi-kyung Kim, M. Son, Mi-Kyung Kim, 2008, European journal of pharmacology.

In vivo gastric residence and gastroprotective effect of floating gastroretentive tablet of DA-9601, an extract of Artemisia asiatica, in beagle dogs

M. Son, M. Son, M. Kang, 2016, Drug design, development and therapy.

Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes.

Mi-kyung Kim, Ye-Hwang Cheong, M. Son, 2016, European journal of pharmacology.

Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice

Mi-kyung Kim, M. Son, Y. Chae, 2015, PloS one.

Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently.

B. Kaang, Mi-kyung Kim, Ye-Hwang Cheong, 2012, Biochemical and biophysical research communications.

Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models

M. Son, E. Yang, G. Ahn, 2016, Archives of Pharmacal Research.

A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.

M. Son, Myung-Shik Lee, Yeon Taek Jeong, 2011, Diabetes research and clinical practice.

The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes

Mi-kyung Kim, M. Son, H. Moon, 2011, Archives of pharmacal research.